Lakefront Biotherapeutics

General ticker "GLPGF" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $2.0B (TTM average)

Lakefront Biotherapeutics does not follow the US Stock Market performance with the rate: -37.4%.

Estimated limits based on current volatility of 0.0%: low 35.15$, high 35.15$

Factors to consider:

  • Total employees count: 452 (-35.8%) as of 2025
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [26.55$, 47.75$]
  • 2026-12-31 to 2027-12-31 estimated range: [25.77$, 46.75$]

Financial Metrics affecting the GLPGF estimates:

  • Positive: with PPE of 5.3 at the end of fiscal year the price was neutral
  • Negative: negative Operating cash flow
  • Positive: Operating profit margin, % of 42.23 > 34.01
  • Positive: Investing cash flow per share per price, % of 13.01 > 2.40
  • Positive: 6.94 < Return on assets ratio (scaled to [-100,100]) of 8.61
  • Negative: Shareholder equity ratio, % of 94.99 > 81.82
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: negative Industry operating income (median)

Similar symbols

Short-term GLPGF quotes

Long-term GLPGF plot with estimates

Financial data

YTD 2023-12-31 2024-12-31 2025-12-31
Operating Revenue €239.72MM €275.65MM €1,111.83MM
Operating Expenses €327.99MM €463.99MM €642.35MM
Operating Income €-88.26MM €-188.34MM €469.48MM
Non-Operating Income €93.89MM €185.25MM €-168.72MM
Interest Expense €1.65MM €0.32MM €2.22MM
R&D Expense €241.29MM €335.46MM €416.89MM
Income(Loss) €5.62MM €-3.08MM €300.76MM
Taxes €9.61MM €-1.80MM €-18.61MM
Net Income(Loss)* €211.70MM €74.08MM €320.76MM
Stockholders Equity €2,795.57MM €2,896.94MM €3,234.66MM
Inventory €73.98MM €51.19MM €22.48MM
Assets €4,357.40MM €4,135.72MM €3,405.24MM
Operating Cash Flow €-405.97MM €-320.03MM €-196.93MM
Capital expenditure €19.27MM €82.11MM €13.70MM
Investing Cash Flow €71.19MM €220.60MM €228.28MM
Financing Cash Flow €-5.00MM €-4.92MM €-3.27MM
Earnings Per Share** €3.21 €1.12 €4.87

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.